Affiliation: King's College London
- Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlEmanuele De Rinaldis
Breakthrough Breast Cancer Research Unit, Division of Cancer Studies, School of Medicine, King s College London, Guy s Hospital, London, UK
BMC Genomics 14:643. 2013....
- Comparative immunohistochemical analysis of ochratoxin A tumourigenesis in rats and urinary tract carcinoma in humans; mechanistic significance of p-S6 ribosomal protein expressionPatrycja Gazinska
Breakthrough Breast Cancer Research Unit, Guy s Hospital, King s Health Partners AHSC, King s College London School of Medicine, London SE1 9RT, UK
Toxins (Basel) 4:643-62. 2012....
- Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic valueShalaka Joshi
Department of Research Oncology, King s College London, Faculty of Life Science and Medicine, Division of Cancer Studies, Bermondsey Wing, Guy s Hospital, London, UK
BMC Cancer 15:546. 2015..Even for Ki67, one of the most widely-studied markers, disagreements over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise and make data more reproducible...
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins
Breakthrough Breast Cancer Research Unit, King s College London, London, United Kingdom Institute for Mathematical and Molecular Biomedicine, King s College London, London, United Kingdom Department of Research Oncology, King s Health Partners AHSC, Life Sciences and Medicine, King s College London, London, United Kingdom
Cancer Discov 5:488-505. 2015..Our data therefore provide a mechanistic association between HORMAD1 expression, a specific pattern of genomic instability, and an association with response to platinum-based chemotherapy in TNBC...